
Opinion|Videos|December 2, 2024
Dosing Frequency and Formulary Decisions for Bispecific Antibodies
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how when selecting between weekly and biweekly dosing schedules for talquetamab and teclistamab in multiple myeloma treatment, health care institutions must carefully weigh factors like patient convenience, monitoring requirements, resource utilization, and total cost of care alongside clinical outcomes to determine optimal treatment pathways for both patient and health system benefits.
Advertisement
Episodes in this series

Video content above is prompted by the following
- Specifically, for talquetamab and teclistamab, how has your institution standardized selection of weekly or biweekly dosing, and how do these different dosing frequencies differ in terms of impact on the health system and patient?
- What additional factors should be considered when making formulary decisions regarding the 3 currently available bispecific antibodies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
2
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
3
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
4
Why Patients Stop Using Their CGMs—and How Pharmacists Can Help
5



































































































































